When was Angle founded?

Angle was founded in 1994 and raised its 1st funding round 21 years after it was founded.

Where is Angle located?

Angle is headquartered in Surrey, Canada.

Who is the current CEO of Angle?

Andrew Newland of Angle. They are also an angel investors in 1 startup.

How many employees does Angle have?

As of Jul 01, 2024, the latest employee count at Angle is 51 - 200.

Is Angle a funded company?

Angle is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Feb 26, 2015.

When was the latest funding round of Angle?

Angle's latest funding was a $***** Post IPO round on Jul 15, 2022, with participation from 0 investor.

Where does Angle rank among its competitors?

Angle ranks 12th amongst 132 active competitors, of which 53 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was 4baseCare, which secured $9.82M in Jan, 2026.

Who are the top competitors of Angle?

Angle's top competitors include Personalis, Delfi Diagnostics and Freenome Health. Among them, 4baseCare secured the most recent funding round in January, 2026.

Angle - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of cancer cell capture and analysis equipment. The company uses liquid biopsy technology and develops Parsortix PC1 Clinical System a medical device for the capture and harvest of intact circulating tumor cells (CTCs) from metastatic breast cancer (MBC) patient blood for user-validated analysis.

Website: angleplc.com
Social

Key Metrics

Founded Year

1994

Location

Surrey, Canada

Stage

Public

Latest Funding Round

Post IPO, Jul 15, 2022, $*****

Investors

WG Partners & 2 more

Ranked

12^th among 132 active competitors

Employee Count

51 - 200 as on Jul 01, 2024

Investment & Acquisitions

Axela & 1 more

Similar Companies

Personalis & 152 more

Exit Details

Public

View Angle's full profile

Angle got listed on Mar 17, 2004.

Click here to take a look at Angle's IPO in detail

Angle has raised funding over 6 rounds. Its first funding round was on Feb 26, 2015. Angle has 3 institutional investors.

Here is the list of recent funding rounds of Angle:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 15, 2022	9336841	Post IPO	4984752	2545362	3086618	8629680
Oct 30, 2020	6640748	Post IPO	6332991	1856229	8687053	4540061
Jun 25, 2018	3677814	Post IPO	5982935	5113176	6757741	6155400

Access funding benchmarks and valuations. Sign up today!

View details of Angle's funding rounds and investors

The founders of Angle is Andrew Newland.

Here are the details of Angle's key team members:

Andrew Newland: Founder & CEO of Angle. They are also an angel investor in 1 startup.
Contact Info: 1 email address

View details of Angle's Founder profiles and Board Members

Angle's employee count trend

Angle has 51 - 200 employees as of Jul 24. Here is Angle's employee count trend over the years:

Uncover Angle's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Angle include Personalis, Delfi Diagnostics and Freenome Health. Here is the list of Top 10 competitors of Angle, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Personalis 2011, Menlo Park (United States), Public	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 4 others	73/100
2nd	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	DFJ Growth, Orbimed & 18 others	68/100
3rd	Freenome Health 2014, United States, Series E	Provider of a deep learning platform for detecting circulating cancer-related markers	$1.35B	Perceptive Advisors, RA Capital Management ... & 65 others	66/100
4th	4baseCare 2018, Bengaluru (India), Series B	Provider of precision oncology solutions, including genomic testing and digital health	$22.3M	Tremis Consultancy, Yali Capital & 55 others	63/100
5th	Ultivue 2015, Cambridge (United States), Series D	Provider of test panels for personalized cancer therapies	$105M	Northpond Ventures, Arch Venture Partners ... & 7 others	63/100
6th	ACT Genomics 2014, Taipei (Taiwan), Acquired	Clinical and research services in genomics for cancer	$20.5M	CLSA Capital Partners, Hotung Investment Holdings ... & 9 others	62/100
7th	Personal Genome 2010, Baltimore (United States), Acquired	Provider of advanced technology solutions for cancer genome analysis	$327M	New Enterprise Associates, Camden Partners ... & 17 others	61/100
8th	Predicta Biosciences 2023, Boston (United States), Series A	Provider of diagnostic and therapeutic products for oncology	$28.6M	Engine Ventures, Myeloma Solutions Fund & 7 others	59/100
9th	Precede 2021, Boston (United States), Series C	Developer of liquid biopsy platform providing disease-defining biology from blood tests	$57M	5AM Ventures, Lilly Asia Ventures & 6 others	58/100
10th	Olaris 2014, Waltham (United States), Series B	Developer of in-vitro diagnostics for oncology, solid-organ transplant, and neurodegeneration	$62.5K	Innospark Ventures, Massachusetts Life Sciences Center ... & 9 others	57/100
12th	Angle 1994, Surrey (Canada), Public	Developer of cancer cell capture and analysis equipment	-	WG Partners, Mercia & 1 others	55/100